ICICI Securities successfully advises Inventia Healthcare Limited on its equity fund raise from India Life Science Fund-III (InvAscent)

ICICI Securities Limited ("I-Sec") is pleased to announce the successful closure of INR. 1,000 Mn equity fund raise in Inventia Healthcare Limited ("Inventia" or the "Company") from India Life Science Fund-III ("InvAscent"), a leading life sciences focused private equity fund with corpus of USD 250 Mn. This is the second round of funding in the Company. The Company had previously raised funding from PE firm Jacob Ballas.

Highlights of the Transaction:

InvAscent will be acquiring minority stake in the Company. The Company will use the proceeds of the fund raise to accelerate growth of its pharma and nutraceutical business and also deleveraging the Balance sheet

I-Sec acted as the exclusive financial advisor to Inventia for the transaction

I-Sec provided comprehensive sell-side advisory services to Inventia viz. positioning the opportunity to a curated list of leading life sciences focused investors, advising the Company on the valuation, negotiating the term sheets, assisting in the due diligence process, etc.

I-Sec successfully convinced the investor on the Company's business model resilience despite the impact of Covid-19;

I-Sec advised the company on transaction structuring and negotiation of definitive transaction documents

I-Sec worked closely with the Company, InvAscent, the existing investor and their respective advisors to assist in the seamless execution of the transaction

With this deal completion, ICICI Securities continues to demonstrate its ability to guide its clients through unprecedented times and successfully conclude transactions in challenging environment. It clearly depicts I-Sec capabilities to provide high quality transaction advisory services to reputed and high-growth potential businesses.

Inventia is a pharmaceutical development and manufacturing company headquartered in Mumbai with over 30 years of operations. Its focus is on development of value added oral solid dosage formulations ("OSDF"). Over the years, company has developed capabilities in offering end to end solutions in the product development process, right from research and development all the way to final manufacturing and packaging. Company is also venturing into Injectables and Nutraceuticals segments.

Shares of ICICI Securities Ltd was last trading in BSE at Rs.467.2 as compared to the previous close of Rs. 472.9. The total number of shares traded during the day was 9032 in over 665 trades.

The stock hit an intraday high of Rs. 479.3 and intraday low of 467. The net turnover during the day was Rs. 4272462.

Source : Equity Bulls

Keywords